PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) CEO Outlines Next Steps for Promising New Technologies

• Company is targeting $3.8 trillion preventative medicine industry
• Sol-gel delivery system administers CBD-based medicines directly to the brain via nasal passages
• Company R&D includes anti-diabetes and obesity gene therapy and powerful non-addictive painkiller

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) expects to make promising progress in the research and development of a number of exciting products in 2018, according to the company’s chairman, CEO and President Stephen Van Deventer in an audio interview (http://ibn.fm/1SVjY). He explained that, while pharmaceutical and nutraceutical companies are well-established, there is a relatively untapped $3.8 trillion a year industry in preventative medicine. Van Deventer said, “We coined the word ‘PreveCeutical’ for preventive medicine, which would be a combination of pharmaceuticals or nutraceuticals, but in the direction of preventive health.”

PreveCeutical is involved in researching and developing products aimed at preventing ailments before they start, thus improving people’s lifestyles. It is currently working on a number of promising projects, including Sol-gel, an innovative cannabidiol-based nose to brain delivery system being developed to give relief from epileptic seizures, pain, inflammation and other neurological conditions.

Van Deventer added, “As you’ve seen on YouTube (…), these people that have seizures, they take some cannabis oil and the seizures go away. Well, that’s not preventing; that’s actually stopping a seizure. So, we can now take these cannabinoids and infuse them to our Sol-gel, and people [can] take it once a week because it will sit in your mucosa and slowly time-release over one week. We can now get cannabinoids in your system and prevent these seizures from happening.”

The PreveCeutical CEO also spoke about other promising products in the company’s pipeline, including a powerful, non-addictive pain reliever and gene therapy to possibly prevent type 2 diabetes and obesity. The non-addictive pain reliever will be designed to “be stronger than morphine or any of the other opioids out there,” Van Deventer said. “However, it will have a few key elements: one, you can’t get high; two, you cannot create tolerance to it; and three, you cannot get addicted to it.”

He said that the company’s researchers, led by Chief Research Officer Harry Parekh, are keen for these life-changing technologies to be available to the mass market. While the cost of gene therapy can run into millions of dollars, Van Deventer said, “We hope to be able to deliver these gene therapies for thousands of dollars. You can have a few thousand dollars, rather than half a million or millions of dollars.”

Describing milestones for the near future, Van Deventer explained that PreveCeutical is planning some strategic acquisitions. “It would be nice to acquire some assets that are commercially viable now and start generating some revenues.”

The company is looking forward to releasing promising results on its research and development projects by the end of 2018.

For more information, visit the company’s website at www.PreveCeutical.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php